PECAM1 and neoplasm: Regorafenib effectively suppressed tumor vascularization evaluated by dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and microvessel area using immunostaining of endothelial marker CD31 in xenograft models [1, 7].